This is an original summary of long-form commentary and cited research. It is not a diagnosis or treatment plan. Neurodegenerative and psychiatric conditions require individualized medical care.

An “umbrella” idea for hard neurologic disease

In a later installment, A Midwestern Doctor gathers roughly two thousand studies and hundreds of reader reports arguing that DMSO’s mix of properties—circulation support, antioxidant defense, anti-inflammation, membrane penetration, protein stabilization, and cell “wake-up” after shock—makes it unusually suited to disorders neurologists often call untreatable. A collaborating clinician is quoted estimating that a large share of everyday neurology complaints improved when patients tried DMSO under supervision—an anecdote that motivates the article, not a controlled statistic.

Mechanisms emphasized for the nervous system

• Protection of neurons from excitotoxins, metals, chemotherapy “chemobrain,” radiation, and oxygen deprivation
• Possible reversible facilitation of blood–brain barrier transport for some drugs and nutrients
• Reduced blood cell aggregation and leukocyte sticking that can impair microcirculation
• Chemical-chaperone behavior that may stabilize misfolded proteins (relevant to ALS SOD1, polyglutamine diseases, and amyloid biology)
• Mild cholinesterase inhibition overlapping with strategies used in Alzheimer’s drugs

Disease areas covered

Parkinson’s: Models using MPTP, rotenone, and 6-OHDA are cited where DMSO or its metabolite DMS reduced oxidative injury. A case-control hint of lower DMSO exposure among young-onset Parkinson’s patients is presented cautiously. Reader reports range from dramatic IV responses to temporary topical benefit.

ALS and related motor syndromes: Mouse survival and motor scores improved with oral DMSO in some models; protein-stabilizing effects on SOD1 are discussed. A detailed patient story of stopping and restarting DMSO with symptom swings is offered as experiential evidence, while the author notes IV use more often appeared to halt progression than reverse it in clinic experience.

Huntington’s and Alzheimer’s: Lab data on polyglutamine toxicity, amyloid aggregation dynamics, memory tests in streptozotocin and Aβ models, and acetylcholine-related effects are surveyed. DMSO is framed as bioactive—not a blank solvent—yet not a proven disease-modifying therapy by modern regulatory standards.

Psychiatry and stress: Forgotten Russian work linking chronic stress, falling cerebral blood flow, and “neurosis” is summarized; DMSO plus vitamin E performed well as an antioxidant adaptogen pair in that framework.

Development: The article also reviews clinical reports of developmental gains in children with Down syndrome and other neurodevelopmental conditions—claims that deserve independent scrutiny and ethical caution.

Safety, again

The same piece spends substantial space on DMSO’s wide therapeutic window and mostly mild side effects, while listing real risks: skin irritation, odor, rare allergy, contaminant carry-through, possible potentiation of alcohol/sedatives/chemotherapy, osmotic issues at high IV doses, and special care in fragile or anticoagulated patients. High lab concentrations that injure cells are distinguished from diluted clinical exposures.

Reader takeaway

This chapter is best read as a map of neglected literature and hypotheses about microcirculation and protein misfolding—not as confirmation that DMSO cures Parkinson’s, Alzheimer’s, or ALS. Families facing these diagnoses should prioritize established care, clinical trials where appropriate, and open discussion with neurologists before experimenting.

Source

Original article: How DMSO Heals the Brain and Transforms Neurology — A Midwestern Doctor, The Forgotten Side of Medicine (Apr. 25, 2026). Note: page is marked paid; this draft draws on the substantial publicly returned content.